Taizhou Kangping Medical recalled 3.85 million cartons of BZK Antiseptic Towelettes on July 22, 2025. The recall stems from a lack of assurance of sterility, posing a high risk to users. Consumers and healthcare providers must stop using these towelettes immediately.
Lack of Assurance of Sterility.
Consumers and healthcare providers should stop using this product immediately. Contact Taizhou Kangping Medical Science And Technology Co., Ltd. or your healthcare provider for guidance. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recall involves BZK Antiseptic Towelettes containing benzalkonium chloride 0.13%. The affected lot numbers are 220583459, 230553459, 232743459, 110523, 031524, 052224, and 247793459. These products were distributed in New York.
The recalled antiseptic towelettes lack assurance of sterility. This poses a significant health risk, especially in professional settings where sterility is critical.
No specific incidents of illness or injury have been reported at this time. The high hazard level reflects potential risks associated with non-sterile products.
Stop using the affected towelettes immediately. Contact Taizhou Kangping Medical Science And Technology Co., Ltd. or your healthcare provider for further guidance.
For more information, reach out to Taizhou Kangping Medical at their official website or via the FDA's recall notice.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.